14 Jun

Broadcom Cuts Revenue Guidance on Expected Weak Chip Demand

WRITTEN BY Sneha Nahata

Broadcom stock sinks

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant’s fiscal 2019 second-quarter earnings release. It missed analysts’ revenue estimate and cut its fiscal 2019 (ending in October) revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

Choppy demand for chips driven by US-China trade tensions weakened Broadcom’s revenue, as did the US government’s ban on Huawei Technologies. The company generated ~$900 million (4% of its overall sales) from Huawei last year.

Broadcom Cuts Revenue Guidance on Expected Weak Chip Demand

Chip stocks fall on Broadcom’s forecast

Broadcom’s forecast of a demand slowdown pulled down chip stocks. Qorvo, Skyworks Solutions, Texas Instruments, NVIDIA, Micron Technology, Qualcomm, NXP Semiconductors, Advanced Micro Devices, and Marvell Technology fell 5.23%, 3.29%, 2.15%, 2.12%, 2.49%, 1.79%, 2.48%, 2.96%, and 2.27%, respectively, after market hours yesterday.

Broadcom stock closed 0.67% higher yesterday at $281.61. The stock has risen 11.74% this year, underperforming the S&P 500, NASDAQ Composite, and Dow Jones Industrial Average, which have risen 15.35%, 18.11%, and 11.91%, respectively.

Latest articles

On November 14, The George Soros Fund Management LLC filed 13F. The firm's total market value was around $3.6 billion at the end of Q3 2019.

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.